Category: MS Research Study and Reports

Fumarates Lead to Lower Infection-Related Healthcare Resource Utilization Relative to Anti-CD20s

May 30, 2025 Key Takeaways A study reveals long-term fumarate therapy significantly reduces infection-related healthcare utilization in multiple sclerosis patients…

Stuart Schlossman

Rebound Effect Not Observed With Multiple Sclerosis Therapy Ozanimod

Author: Marco Meglio – May 29, 2025 Key Takeaways A recent large cohort analysis of global MS registry data reported…

Stuart Schlossman

Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population

Key Takeaways New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple…

Stuart Schlossman

Featured image for “AI tool effectively measures MS disease activity from 1 MRI scan”

AI tool effectively measures MS disease activity from 1 MRI scan

MindGlide to be used in research to assess brain damage, treatment by Marisa Wexler, MS | April 9, 2025 A…

Stuart Schlossman

Featured image for “ACTRIMS 2025: Tolebrutinib impact greater in MS patients with PRLs”

ACTRIMS 2025: Tolebrutinib impact greater in MS patients with PRLs

Treatment candidate found effective in reducing disability progression risk by Andrea Lobo, PhD | March 5, 2025 — #ACTRIMS Sanofi’s experimental BTK inhibitor tolebrutinib is…

Stuart Schlossman

Featured image for ““Breaking Barriers: The Potential of CAR-T Cell Therapy in Multiple Sclerosis””

“Breaking Barriers: The Potential of CAR-T Cell Therapy in Multiple Sclerosis”

CLICK HERE, – to listen to this Round Table discussion To stay up to date with MS news, patient programs,…

Stuart Schlossman

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis

December 2024 The DOT-MS Randomized Clinical Trial Full article including the research team JAMA Neurol. Published online December 9, 2024. doi:10.1001/jamaneurol.2024.4164…

Stuart Schlossman

New Study Indicates MS May Worsen During Menopause

Researchers at the University of California – San Francisco found that menopause onset is associated with increased functional decline and…

Stuart Schlossman

Smoldering MS: the real MS becomes a tractable problem

Tolebrutinib, a second-generation BTK inhibitor, is the first to show a reduction in disability accumulation in non-relapsing secondary progressive MS…

Stuart Schlossman

Featured image for “2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD”

2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD

For those not sure the reason for this criteria, is it to help doctors Diagnose MS Author(s): Peter A. Calabresi,…

Stuart Schlossman

Categories

Latest Blog Posts